In myeloid malignancies, early trial results failed to show the clinical benefit of anti-PD-1 as monotherapy in AML (236) or high-risk MDS (237) and CTLA-4 blockade using ipilimumab in high-risk MDS (238). This evidence concerns the gene CTLA4 and myelodysplastic syndrome.